CMTA:NSD-Clementia Pharmaceuticals Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 26.35

Change

0.00 (0.00)%

Market Cap

USD 1.00B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Company Website : http://www.clementiapharma.com

Address : 4150 Sainte-Catherine Street West, Suite 550 H3Z 2Y5,Montreal,CAN

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.60

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

 USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

 USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

 USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

 USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

 USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

 USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

 USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

 USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

 USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

 USD38,513.36B N/A N/A

ETFs Containing CMTA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 24.63% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.63% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.65% N/A N/A N/A N/A
Risk Adjusted Return 45.07% N/A N/A N/A N/A
Market Capitalization 1.00B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.80 N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.60 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike